Skip to main content

6 Result(s)

within English Remove this filter Cancer Research Remove this filter Oncology Remove this filter G. Masi Remove this filter

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer

Include preview-only content

  1. Article

    Open Access

    Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

    The FOLFOXIRI regimen produces a high rate of radiological and histopathological responses. Bevacizumab added to chemotherapy showed an improvement in pathological response and necrosis of colorectal liver met...

    F Loupakis, M Schirripa, C Caparello, N Funel, L Pollina… in British Journal of Cancer (2013)

    Download PDF (472 KB) View Article

  2. Article

    Open Access

    Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

    The identification of molecular and genetic markers to predict or monitor the efficacy of bevacizumab (BV) represents a key issue in the treatment of metastatic colorectal cancer (mCRC).

    F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore… in British Journal of Cancer (2011)

    Download PDF (285 KB) View Article

  3. Article

    Open Access

    KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

    KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutati...

    F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore… in British Journal of Cancer (2009)

    Download PDF (350 KB) View Article

  4. Article

    Open Access

    A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

    The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substitut...

    E Vasile, G Masi, L Fornaro, S Cupini, F Loupakis, S Bursi… in British Journal of Cancer (2009)

    Download PDF (156 KB) View Article

  5. Article

    Open Access

    Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy

    We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC). The t...

    F Graziano, A Ruzzo, F Loupakis, D Santini, V Catalano… in British Journal of Cancer (2008)

    Download PDF (149 KB) View Article

  6. Article

    Open Access

    A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

    The pharmacokinetics (PK) and pharmacodynamics (PD) of metronomic irinotecan have not been studied in cancer patients. The aim of the study is to investigate the PK/PD profile of irinotecan/SN-38 administered ...

    G Allegrini, A Falcone, A Fioravanti, M T Barletta, P Orlandi… in British Journal of Cancer (2008)

    Download PDF (256 KB) View Article